[go: up one dir, main page]

IL117592A - N-substituted sulfonamidobenzene compounds - Google Patents

N-substituted sulfonamidobenzene compounds

Info

Publication number
IL117592A
IL117592A IL11759292A IL11759292A IL117592A IL 117592 A IL117592 A IL 117592A IL 11759292 A IL11759292 A IL 11759292A IL 11759292 A IL11759292 A IL 11759292A IL 117592 A IL117592 A IL 117592A
Authority
IL
Israel
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
IL11759292A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL117592A publication Critical patent/IL117592A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11759292A 1991-08-02 1992-07-31 N-substituted sulfonamidobenzene compounds IL117592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
IL102703A IL102703A (en) 1991-08-02 1992-07-31 N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IL117592A true IL117592A (en) 1999-04-11

Family

ID=9415909

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11759292A IL117592A (en) 1991-08-02 1992-07-31 N-substituted sulfonamidobenzene compounds
IL102703A IL102703A (en) 1991-08-02 1992-07-31 N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them
IL11759296A IL117592A0 (en) 1991-08-02 1996-03-21 N-substituted sulfonamidobenzene compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL102703A IL102703A (en) 1991-08-02 1992-07-31 N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them
IL11759296A IL117592A0 (en) 1991-08-02 1996-03-21 N-substituted sulfonamidobenzene compounds

Country Status (28)

Country Link
EP (1) EP0526348B1 (xx)
JP (1) JP2633085B2 (xx)
KR (1) KR100241583B1 (xx)
AT (1) ATE163289T1 (xx)
AU (2) AU658664B2 (xx)
BR (1) BR9205336A (xx)
CA (2) CA2093221C (xx)
CZ (1) CZ288173B6 (xx)
DE (1) DE69224450T2 (xx)
DK (1) DK0526348T3 (xx)
ES (1) ES2117038T3 (xx)
FI (2) FI104069B (xx)
FR (1) FR2679903B1 (xx)
HU (2) HUT68927A (xx)
IL (3) IL117592A (xx)
LT (1) LT3064B (xx)
LV (1) LV10091B (xx)
MX (1) MX9204487A (xx)
MY (1) MY110517A (xx)
NO (1) NO180047C (xx)
NZ (1) NZ243795A (xx)
PH (1) PH30661A (xx)
RU (1) RU2104268C1 (xx)
SG (1) SG47501A1 (xx)
SK (1) SK283463B6 (xx)
UA (1) UA27238C2 (xx)
WO (1) WO1993003013A1 (xx)
ZA (1) ZA925781B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1001973A1 (en) * 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
EP0994896A1 (en) * 1997-07-31 2000-04-26 Elan Pharmaceuticals, Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
FR2775598A1 (fr) * 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100711840B1 (ko) 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Ｖｌａ-4 관련 질환 치료용 아실 유도체
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1150997A1 (en) * 1999-01-25 2001-11-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
EP1335901B1 (en) 2000-10-17 2010-04-14 Merck Serono SA Pharmaceutically active sulfanilide derivatives
US7056910B2 (en) 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
US7468385B2 (en) 2001-12-20 2008-12-23 Laboratoires Serono Sa Triazoles as oxytocin antagonists
EP2399903A1 (en) * 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1587788B9 (en) * 2002-09-17 2007-10-24 F. Hoffmann-La Roche Ag 2,7-substituted indoles and their use as 5-ht6 modulators
CN1301970C (zh) * 2002-09-17 2007-02-28 弗·哈夫曼-拉罗切有限公司 2,4－取代吲哚和它们作为5－ht6调节剂的用途
KR20050043988A (ko) * 2002-10-11 2005-05-11 액테리온 파마슈티칼 리미티드 설포닐아미노-아세트산 유도체 및 오렉신 수용체길항제로서 이들의 용도
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
EP1806340B1 (en) * 2004-10-27 2011-05-04 Kissei Pharmaceutical Co., Ltd. Indoline compound and process for producing the same
DE602006020754D1 (de) 2005-09-29 2011-04-28 Elan Pharm Inc Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
AU2006297220B8 (en) 2005-09-29 2013-01-31 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由ｖｌａ-４所調節的白血球黏附之嘧啶磺醯胺化合物
SG175355A1 (en) 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
IL102703A (en) 1997-03-18
HU9300951D0 (en) 1993-06-28
UA27238C2 (uk) 2000-08-15
FI107048B (fi) 2001-05-31
WO1993003013A1 (fr) 1993-02-18
FI104069B1 (fi) 1999-11-15
SK283463B6 (sk) 2003-08-05
FI980175L (fi) 1998-01-27
LV10091A (lv) 1994-05-10
AU658664B2 (en) 1995-04-27
JPH06501960A (ja) 1994-03-03
NO180047B (no) 1996-10-28
ZA925781B (en) 1993-03-02
FI931476A0 (fi) 1993-04-01
HUT68927A (en) 1995-08-28
FI104069B (fi) 1999-11-15
HK1008741A1 (en) 1999-05-14
NO180047C (no) 1997-02-05
FR2679903A1 (fr) 1993-02-05
JP2633085B2 (ja) 1997-07-23
ATE163289T1 (de) 1998-03-15
FR2679903B1 (fr) 1993-12-03
FI980175A0 (fi) 1998-01-27
DK0526348T3 (da) 1998-11-23
DE69224450T2 (de) 1998-07-30
MX9204487A (es) 1993-02-01
FI931476A7 (fi) 1993-04-01
IL102703A0 (en) 1993-01-14
ES2117038T3 (es) 1998-08-01
LT3064B (en) 1994-10-25
NO931262L (no) 1993-05-26
IL117592A0 (en) 1996-07-23
AU1154195A (en) 1995-05-04
RU2104268C1 (ru) 1998-02-10
CZ68293A3 (en) 1994-01-19
HU211884A9 (en) 1995-12-28
CA2093221A1 (en) 1993-02-03
CA2093221C (en) 1998-09-22
CA2206776A1 (en) 1993-02-03
EP0526348B1 (fr) 1998-02-18
PH30661A (en) 1997-09-16
EP0526348A1 (fr) 1993-02-03
CZ288173B6 (en) 2001-05-16
AU2475892A (en) 1993-03-02
LV10091B (en) 1995-04-20
KR100241583B1 (ko) 2000-03-02
AU691223B2 (en) 1998-05-14
CA2206776C (en) 2002-02-26
BR9205336A (pt) 1993-11-16
LTIP114A (en) 1994-06-15
SG47501A1 (en) 1998-04-17
NZ243795A (en) 1995-04-27
MY110517A (en) 1998-07-31
NO931262D0 (no) 1993-04-01
DE69224450D1 (de) 1998-03-26
SK42693A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
IL117592A0 (en) N-substituted sulfonamidobenzene compounds
IL110820A0 (en) N-substituted heterocyclic derivatives and their preparation
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
EP0659412A3 (en) Inhibition of premenstrual synchronous symptoms / dysphoric disorder of the late luteal phase.
HUP9901630A2 (hu) Új indol-2,3-dion-3-oxim-származékok
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
DE3783657D1 (de) Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
IE36710B1 (en) Hydrazinopyridazine derivatives
TW197420B (xx)
WO2003068736A3 (en) Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof
FR2138488A1 (en) 1-(5-indanyl)-omega-aminoalkanes - with tranquillizing activity
ES8603377A1 (es) Un procedimiento para la preparacion de nuevos derivados de feniletanamina.
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok
ES8404362A1 (es) Un procedimiento para preparar nuevos compuestos de cefem.
IL99819A0 (en) Imidazole-2-yl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees